Novel mouse monoclonal antibodies specifically recognizing β-(1→3)-D-glucan antigen

PLoS One. 2019 Apr 25;14(4):e0215535. doi: 10.1371/journal.pone.0215535. eCollection 2019.

Abstract

β-(1→3)-D-Glucan is an essential component of the fungal cell wall. Mouse monoclonal antibodies (mAbs) against synthetic nona-β-(1→3)-D-glucoside conjugated with bovine serum albumin (BSA) were generated using hybridoma technology. The affinity constants of two selected mAbs, 3G11 and 5H5, measured by a surface plasmon resonance biosensor assay using biotinylated nona-β-(1→3)-D-glucan as the ligand, were approximately 11 nM and 1.9 nM, respectively. The glycoarray, which included a series of synthetic oligosaccharide derivatives representing β-glucans with different lengths of oligo-β-(1→3)-D-glucoside chains, demonstrated that linear tri-, penta- and nonaglucoside, as well as a β-(1→6)-branched octasaccharide, were recognized by mAb 5H5. By contrast, only linear oligo-β-(1→3)-D-glucoside chains that were not shorter than pentaglucosides (but not the branched octaglucoside) were ligands for mAb 3G11. Immunolabelling indicated that 3G11 and 5H5 interact with both yeasts and filamentous fungi, including species from Aspergillus, Candida, Penicillium genera and Saccharomyces cerevisiae, but not bacteria. Both mAbs could inhibit the germination of Aspergillus fumigatus conidia during the initial hours and demonstrated synergy with the antifungal fluconazole in killing C. albicans in vitro. In addition, mAbs 3G11 and 5H5 demonstrated protective activity in in vivo experiments, suggesting that these β-glucan-specific mAbs could be useful in combinatorial antifungal therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology*
  • Antifungal Agents / immunology
  • Antifungal Agents / pharmacology*
  • Antigens, Fungal / immunology*
  • Aspergillus fumigatus / drug effects
  • Aspergillus fumigatus / immunology
  • Candida albicans / drug effects
  • Candida albicans / immunology
  • Candidiasis / drug therapy*
  • Candidiasis / immunology
  • Candidiasis / microbiology
  • Cell Wall / drug effects
  • Cell Wall / immunology
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Female
  • Fluconazole / pharmacology
  • Humans
  • Mice
  • Microbial Sensitivity Tests
  • Treatment Outcome
  • beta-Glucans / immunology*

Substances

  • Antibodies, Monoclonal
  • Antifungal Agents
  • Antigens, Fungal
  • beta-Glucans
  • Fluconazole

Supplementary concepts

  • Systemic candidiasis

Grants and funding

Synthesis of biotinylated oligosaccharids and of BSA-based glycoconjugate immunogen were supported by Russian Science Foundation (http://rscf.ru; grant 14-50-00126; in part to D.V. Yashunsky), assaying of antibodies on glycoarray was supported by Russian Science Foundation (http://rscf.ru; grant 14-23-00199 to N.E. Nifantiev); development of mouse mAbs, SPR-study, and confocal microscopy (in part) were supported by Russian Science Foundation (http://rscf.ru; grant 16-14-00083 to N.V. Tikunova); microorganisms used in this work were provided by the Collection of Extremophile Microorganisms and Type Cultures (developed within Project 0309-2017-0008 granted by the Russian Federal Agency of Scientific Organizations; www.fano.gov.ru); study of the recognition of cell cultures by monoclonal antibodies was supported by the Franco-German ANR-DFG (ANR-16-CE92-0031-01 AFUINTERACT to V. Kumar; (http://www.agence-nationale-recherche.fr) and the Franco-Indian CEFIPRA (Project N° 5403-1 to V. Kumar) grants.